|
Oct 11
|
MaxCyte to Report Third Quarter 2024 Financial Results on November 6, 2024
|
|
Oct 10
|
MaxCyte Appoints Ali Soleymannezhad as Chief Commercial Officer
|
|
Oct 9
|
MaxCyte Inc (MXCT) Q2 2024 Earnings Call Highlights: Revenue Growth Amid Core Challenges
|
|
Jun 14
|
President of MaxCyte Maher Masoud Buys More Stock
|
|
Jun 13
|
Does MaxCyte (MXCT) Have the Potential to Rally 85% as Wall Street Analysts Expect?
|
|
Jun 13
|
Recent Price Trend in MaxCyte (MXCT) is Your Friend, Here's Why
|
|
Jan 23
|
MaxCyte Signs Strategic Platform License with Imugene to Advance their Cancer Immunotherapy Programs
|
|
Jan 2
|
MaxCyte Confirms Appointment of Maher Masoud as President, Chief Executive Officer and Director
|
|
Dec 19
|
Hedge Funds Say These Penny Stocks Are Poised to Explode
|
|
Dec 7
|
Insider Sell Alert: President and CEO Douglas Doerfler Sells 124,450 Shares of MaxCyte Inc (MXCT)
|
|
Dec 2
|
Insider Sell Alert: President and CEO Douglas Doerfler Sells 25,550 Shares of MaxCyte Inc (MXCT)
|
|
Aug 9
|
MaxCyte Reports Second Quarter and Half-Year 2023 Financial Results and Updates Full Year 2023 Guidance
|
|
Jul 13
|
MaxCyte to Report Second Quarter 2023 Financial Results on August 9, 2023
|
|
Apr 28
|
MaxCyte, Inc. (LON:MXCT) insider upped their holding by 400% earlier this year
|